drugset
drugset / Trial / NCT03058705

Near Infrared Fluorescence Imaging for Bladder Cancer Detection

NCT03058705 ↗

Completed 10 enrolled Edward Messing Imagin Medical · collab
NaSingle-groupOpen-labelDevice feasibility

Summary

The primary outcome of this study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumors using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).

Timeline

Start
2017-11-28
Primary completion
2018-07-25
Completion
2018-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject hexaminolevulinate Small molecule 100 mg Other

Indications

urinary bladder cancer